
Cochrane Said Leqembi Doesn’t Work. Why Didn’t Anyone Seem to Care?
COCHRANE SERIES, PART 1 – WHAT HAPPENED:
A respected review called a breakthrough Alzheimer’s drug useless. Experts shrugged. Investors, who normally panic on such news, barely noticed. Here’s why that matters — and what it means for families weighing their options.



























